ADHD Trial, Recruiting NCT07565402 Sponsor: Nanjing Medical University Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT07565402
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with ADHD (Attention-Deficit/Hyperactivity Disorder) based on standard diagnostic guidelines (DSM-5), confirmed through a structured interview tool called the DIVA-5 (Chinese version).
  • People aged between 18 and 55 years.
  • People who are right-handed.
  • People who are willing to take part voluntarily and have signed a written consent form.

Who may not be able to join:

  • People who have a neurological condition (such as epilepsy) or another mental health condition alongside ADHD.
  • People who have a serious physical illness.
  • People who have received electroconvulsive therapy (ECT) or similar physical treatments within the past 6 months before joining the trial.
  • People who are planning to change their ADHD medication before the trial's final follow-up appointment.
  • People who have medical implants or devices that would make a non-invasive brain stimulation treatment called tDCS unsafe — for example, metal implants in the skull, electronic brain implants, or skull plates (confirm with trial site if unsure whether a specific implant applies).
  • People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chun Wang, PhD, Nanjing Brain Hospital

Phone: 15850566376

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nanjing Medical University
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
21 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in ADHD symptoms as measured by the Adult ADHD Self-Report Scale (ASRS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov